Sector: MedicalPROVECTUS PHARM (OTCBB: PVCT)
Headlines
- Interim Phase 2 Survival Data for PV-10 Shows Markedly Longer Overall and Disease Specific Survival for Subjects Responsive to PV-10
Nov 23, 2009 07:00 AM | PVCT
- NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Nov 20, 2009 03:02 PM | CYCC, ECTE, EMIS, INO, PVCT
- Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009
Nov 17, 2009 07:00 AM | PVCT
- Provectus Pharmaceuticals Initiates Compassionate Use Program of PV-10 for Non-Visceral Indications in Cancer Patients in U.S.
Oct 14, 2009 07:00 AM | PVCT
- Provectus Initiates Phase 1 Trial of PV-10 for Liver Cancer
Oct 01, 2009 07:00 AM | PVCT
- BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome
Sep 22, 2009 12:42 PM | DNA, INCY, NDN, PVCT
- Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma
Sep 21, 2009 07:30 AM | PVCT
- Provectus Pharmaceuticals Will Present at the Maxim Group Growth Conference on September 29, 2009
Sep 16, 2009 12:35 PM | PVCT
- Taking Cancer Treatment To A New Level (OTC: PVCT)
Sep 16, 2009 11:04 AM | PVCT
- Provectus Pharmaceuticals Will Present at the Rodman & Renshaw 11th Annual Healthcare Conference on September 10, 2009
Sep 01, 2009 08:01 AM | PVCT
- SCIA "Saturday Winter Conference"
Nov 24, 2009 09:51 AM | PVCT
- Video: Provectus Pharmaceuticals Updates Shareholders On 2009 Year-To-Date Accomplishments
Aug 11, 2009 10:56 AM | PVCT
- Provectus Pharmaceuticals Initiates New PH-10 Clinical Study for Psoriasis
Jul 20, 2009 08:10 AM | PVCT
- Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Jul 01, 2009 06:46 AM | PVCT
- Provectus Pharmaceuticals to Offer Compassionate Use of PV-10 for Non-Visceral Indications in Cancer Patients
Jun 22, 2009 10:44 AM | PVCT
- Video: Provectus Reports Encouraging Clinical Data at ASCO on Treatment of Metastatic Melanoma With PV-10
Jun 01, 2009 08:02 AM | PVCT
- Provectus Reports on Presentation of Chemoablation of Metastatic Melanoma from Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology
May 18, 2009 08:11 AM | PVCT
- Provectus Completes Patient Accrual in Phase 2 Trial of PV-10 for Metastatic Melanoma
May 14, 2009 10:20 AM | PVCT
- Provectus Pharmaceuticals Explains Recent S-1/A Filing
May 06, 2009 08:13 AM | PVCT
- Provectus Abstract Titled “Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)" to be Presented at ASCO Scientific Program on June 1 in Orlando
Apr 28, 2009 08:14 AM | PVCT
- Form 4 PROVECTUS PHARMACEUTICAL For: Aug 26 Filed by: WACHTER ERIC PHD (10K)
Aug 27, 2009 04:50 PM
- Form 4 PROVECTUS PHARMACEUTICAL For: Jul 17 Filed by: WACHTER ERIC PHD (10K)
Jul 20, 2009 12:08 PM
- Form 4 FUCHS STUART For: Jul 08 (10K)
Jul 08, 2009 01:50 PM
- Form 4 PROVECTUS PHARMACEUTICAL For: Jun 19 Filed by: WACHTER ERIC PHD (10K)
Jun 19, 2009 03:07 PM
- Form 4 PROVECTUS PHARMACEUTICAL For: Jun 19 Filed by: SCOTT TIMOTHY PHD (10K)
Jun 19, 2009 03:04 PM
- Form 4 McMasters Kelly M For: Jun 19 (10K)
Jun 19, 2009 03:04 PM
- Form 4 FUCHS STUART For: Jun 19 (10K)
Jun 19, 2009 02:59 PM
- Form 4 DEES H CRAIG For: Jun 19 (10K)
Jun 19, 2009 02:56 PM
- Form 4 CULPEPPER PETER R For: Jun 11 (10K)
Jun 11, 2009 04:49 PM
- Form 4 PROVECTUS PHARMACEUTICAL For: Jun 08 Filed by: WACHTER ERIC PHD (10K)
Jun 09, 2009 07:03 PM
Analyst Ratings
Share Performance
|
Period
|
PVCT
|
Compare to S&P
|
| YTD |
16.30 %
|
-3.74 %
|
| 4 Weeks |
17.58 %
|
16.31 %
|
| 12 Weeks |
16.30 %
|
9.65 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
